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Susceptibility to Abdominal Aortic Aneurysm or Aortoiliac Occlusive
Disease
Korcz A, Mikolajczyk-Stecyna J, Gabriel M, et al. J Surg Res 2009;153:76-82.
Conclusion: Gene polymorphism of the angiotensin-converting en-
zyme gene (ACE, I/D) does not predispose to aortoiliac occlusive disease
(AIOD) but may be a factor in development of abdominal aortic aneurysm
(AAA) when combined with hypertension.
Summary: In 1992 Cambien et al noted an association between
angiotensin-converting enzyme (ACE, I/D) gene polymorphisms with
coronary artery disease and myocardial infarction. ACE levels in plasma and
tissue are under genetic control, and about 50% of the ACE plasma level
variability is associated with I/D gene polymorphism (Nature 1992;359:
641-4 and J Clin Invest 1990;86:1343-47). It is thought that an increase in
ACE plasma levels affects angiotensin plasma levels, which can affect remod-
eling of vascular tissue in atherosclerosis. ACE D allele carriers have higher
ACE plasma and tissue levels compared with those with I/D and II geno-
types. ACE DD homozygotes have approximately twice higher levels of
angiotensin 2 than do II homozygotes, with I/D individuals having inter-
mittent ACE concentrations. The authors investigated 829 individuals with
aortoiliac disease or controls. There were 133 patients with AAA, 152 with
AIOPD, and a random Polish population of 392 patients who underwent
ACE I/D gene polymorphism analysis. Analysis was performed by polymer-
ase chain reaction and gel electrophoresis. Results indicated that genotype
distribution and allele frequency ofACE I/Dwere not significantly different
between patients with AAA or AIOD vs the control group. Differences were
found in hypertensive patients with AAA vs normotensive patients with AAA
(odds ratio, 3.05; 95% confidence interval, 1.22-7.79; P  .015) and
hypertensive patients with AAA vs the population group (odds ratio, 2.56;
95% confidence interval, 1.27-5.16; P  .007). There was no relationship
between ACE gene polymorphism and hypertension in the AIOD group.
Comment: There have been mixed results analyzing the effects of
polymorphisms of the ACE gene in the development of AAA. Patients in this
study were Polish, whereas previous studies on Italian patients had suggested
a stronger relationship between ACE polymorphism and development of
AAA (Eur J Vasc Endovasc Surg 2001;21:445-50). Although there may be
ethnic differences in susceptibility to polymorphisms of the ACE gene in the
development of AAA, there are certainly many other unrecognized con-
founding variables and environmental factors that may also lead to these
discrepant observations. Additional studies in other populations, consider-
ing environmental factors and perhaps ethnic variability, will be necessary to
establish the role of the ACE gene in the development of AAA and the
possible benefit of treatment with ACE inhibitors in patients at risk for AAA.
Atherosclerotic Plaque Progression in Carotid Arteries: Monitoring
with High-Spatial-Resolution MR Imaging—Multicenter Trial
Boussel L, Arora S, Rapp J, et al. Radiology 2002;252:789-96.
Conclusion:Magnetic resonance (MR) techniques can document that
the rate of increase in vessel wall volume in patients with pre-existing cardiac
disease is slowed by statin therapy.
Summary: Luminal diameter is the primary imaging variable for defin-
ing progression of carotid stenosis. Diameter is only one way of character-
izing a complex lesion, however, and changes in the luminal diameter may
not reflect plaque remodeling. The authors postulate that geometric and
compositional features of an atherosclerotic plaque might better help define
an unstable plaque. Potential variables include the volume of the plaque,
extent of irregularity of the plaque surface, fibrous cap thickness, and size
and location of the necrotic plaque core. The current study, Monitoring
Atherosclerotic Plaque Progression (MAPP), is a National Institutes of
Health-funded prospective study involving six centers in the United States
and Canada. A primary goal was to estimate the annualized rate of progres-
sion of vessel wall volume in carotid arteries. An additional goal was to
establish how frequently MR studies have acceptable image quality to
determine plaque volume. The study recruited 160 patients with 50%
stenosis of the carotid artery. They underwent prospective imaging of the
carotid arteries at baseline and 1 year later using high spatial resolution 1.5-T
MR imaging. Only studies with acceptable image quality were included. All
160 patients completed both baseline and follow-up studies. Of these, 67.5%
were deemed to have had image quality that was acceptable for a quantitative
analysis. Rejection of images was primarily for motion artifact or deep
location of the artery. The mean annual change in vessel wall volume was
2.31%  10.88%. With follow-up at 1 year, vessel wall volumes in patients
who did not receive statin therapy had increased faster compared with those
280patients who received statin therapy (7.8%  13.58% vs 1.4%  9%,
respectively; P  .029).
Comment: The report indicates quantitative MR imaging can deter-
mine annual rates of progression of carotid wall volume and that statin
therapy appears effective in reducing the rate of progression of carotid wall
volume. The changes measured were real but small and of uncertain clinic
relevance. Statins probably work in a number of ways, and among the
mechanisms are both stabilization of larger existing plaques and retarding of
growth of smaller lesions.
Early Evaluation of Acute Traumatic Coagulopathy by Thrombelasto-
graphy
Carroll RC, Craft RM, Langdon RJ, et al. Transl Res 2009;154:34-9.
Conclusion: PlateletMapping assays correlate with a need for blood
transfusion and abnormal thrombelastogram parameters correlate with
death.
Summary: There is a significant association between post-traumatic
coagulopathy and death. It is postulated that poor perfusion coupled with
shock and tissue factor release along with thrombin generation results in an
imbalance of the thrombin-thrombomodulin-protein C pathway (Ann Surg
2007;245:812-8). Overactivated protein C leads to loss of factors Va and
VIIIa. This results in an impaired coagulation and coagulopathy manifesting as
consumption or dilution of clotting factors, hyperthermia, acidosis, and platelet
dysfunction or consumption (J Trauma 2008;64:s64-8). In this study the
authors sought to determine how early after trauma coagulopathy could be
observed and to assess whether coagulopathy as determined by thrombelas-
togram (TEG) and PlateletMapping correlated with post-traumatic transfu-
sion or death. TEG assays were performed on 161 patients treated at a level
1 trauma center during a 12-month period. Inclusion criteria were an injury
severity score9 and air ambulance transport. The investigators collected a
citrated blood sample at the accident scene before fluid resuscitation. A
second citrated and heparinized blood sample was collected 1 hour of
arrival in the emergency department. Citrated blood samples were analyzed
by the TEG system for reaction (R) time, clot formation (K) time, clotting
rate (angle), strength of clot (maximum amplitude [MA]), and percent
fibrinolysis at 60 minutes (LY60). The heparinized blood sample was
analyzed by PlateletMapping assays for fibrinogen levels and adenosine
diphosphate (ADP)-platelet activation. Comparisons were made between
on-site and emergency department assays and subsequent death or need for
transfusion. No real differences in the TEG parameters were observed from
on-site vs those obtained in the emergency department. TEG parameters did
not correlate with the need for transfusion; however, poor platelet function
observed by PlateletMapping did significantly correlate with need for trans-
fusion. Abnormal ADP-platelet activation was highly correlated with the
need for transfusion (P  .013). There was a significant correlation of all
standard TEG parameters with death. Fibrinogen levels 100 mg/dL, as
determined by PlateletMapping, also significantly correlated with death.
Comment: The study demonstrates coagulopathy can be detected
quickly after trauma and presumably after any event producing acute blood
loss such as rupture of an abdominal or thoracic aneurysm. There was little
difference between TEG parameters measured at the site of the accident vs
those measured in the emergency department. Currently, decisions to
transfuse packed red cells or fresh frozen plasma are empiric. It may be that the
TEG system along with PlateletMapping can provide evidence-based transfu-
sion and more efficient use of blood products in the bleeding patient.
Elective Amputation of the Toes in Severe Lymphedema of the Lower
Leg: Rationale and Indications
Chen H, Gharb BB, Salgad CJ, et al. Ann Plast Surg 2009;63:193-7.
Conclusion: Elective toe amputation in combination with the Charles
procedure reduces long-term morbidity associated with advanced lymphed-
ema of the lower limb.
Summary: In advanced lymphedema, the skin develops a peau
d’orange appearance with papillomatosis and hyperkeratosis. These changes
lead to gradual sealing of the intradigital spaces, with resulting bacterial and
fungal infection and worsening of lymphedema. Between January 1990 and
July 2006, the authors offered an elective Charles procedure along with
disarticulation of the toes to their patients with stage III lymphedema
(elephantiasis with a grossly increased volume of the limb associated with
dermatosclerosis and papillomatosis lesions). Ten patients underwent an
elective Charles procedure accompanied with toe disarticulations, and 24
patients underwent the Charles procedure alone. The Charles procedure was
performed with a pneumatic tourniquet. Subcutaneous tissue and skin was
